Phase 2 Bladder Cancer Trial, Recruiting NCT06091124 Sponsor: RenJi Hospital Condition: Bladder Cancer
Back to Bladder Cancer

Phase 2 Bladder Cancer Trial, Recruiting

NCT06091124
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman aged 18 to 75 years old.
  • You are generally well enough to carry out daily activities, or have only mild limitations (confirm with trial site regarding how this is assessed).
  • You have been diagnosed through a tissue sample with a specific type of bladder cancer that has a strong neuroendocrine (nerve-related) component, making up more than half of the cancer; tissue samples will need to be provided before joining.
  • Your cancer is at a stage that has not spread to distant parts of the body, and surgery to remove the bladder may still be possible (confirm with trial site based on your specific scan results).
  • You are expected to live longer than 3 months.
  • Your blood, liver, and kidney test results are within acceptable ranges, as checked within the 14 days before joining the trial.
  • If you are able to have children, you must agree to use reliable contraception throughout the trial and for 12 months after treatment ends.
  • You are willing to take part voluntarily, sign a consent form, follow the study plan, and attend follow-up appointments.

Who may not be able to join:

  • You have previously received certain types of immunotherapy treatments (anti-PD-1, anti-PD-L1, or anti-CTLA-4 drugs).
  • You have previously received drug treatment for cancer, unless it was a specific type of treatment given directly into the bladder that ended at least one week before the study starts.
  • You have previously had radiation therapy for bladder cancer.
  • You have a known allergy to the study drug (adebrelimab) or any of its ingredients.
  • You have received other cancer treatments, immune-related treatments, or taken part in another clinical trial within the past 4 weeks, or you have not fully recovered from side effects of previous treatments.
  • You are pregnant or currently breastfeeding.
  • You are HIV positive.
  • You have active hepatitis B or C (specific blood test results will be checked to confirm this).
  • You have active tuberculosis.
  • You have an autoimmune disease (where the immune system attacks the body) that has required ongoing medical treatment within the past 2 years.
  • You have other serious uncontrolled health conditions such as severe heart problems, a heart attack in the last 6 months, a stroke in the last 3 months, uncontrolled diabetes, or certain lung conditions.
  • You have received a live vaccine within 4 weeks before starting treatment (note: most standard flu shots are allowed, but nasal spray flu vaccines are not).
  • You have previously had a stem cell transplant or an organ transplant from another person.
  • You have a history of substance misuse or a mental health condition that would make participation difficult.
  • You have fluid build-up in the lungs or abdomen that is causing symptoms or requires treatment.
  • You have had another type of cancer in the past 5 years that has not been fully cleared, with some exceptions for certain easily cured skin or localised cancers (confirm with trial site).
  • You also have cancer in the upper part of your urinary tract (in the kidney or the tube connecting the kidney to the bladder).
  • You have any other serious medical or psychiatric condition that the trial doctors believe could put you at risk or affect the trial results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86 17521674856

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
16 November 2023
Est. completion
1 January 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathologic complete response (ypCR) at cystectomy; Safety and tolerability of combination therapy and radical cystectomy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov